资讯
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Pot
−Pre-SpecifiedInterimAnalysisShowsPositiveSafetyandEfficacyResults;MezagitamabSafeandWellTolerated−TakedaIntendstoInitiateaGlobalPhase3TrialofMezagitamabinPatientswith...